Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 141

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1
Chunk 141
---
 of approval of an MMA in each territory, as defined (e.g., United States, European Union, China, Japan),
the Company will be obligated to pay an approval fee of $66,000 per territory up to a maximum of $300,000 in aggregate, which has not
yet been received as of September 30, 2025. Pursuant to the terms of License Agreement II, upon commercialization, Company will pay a
royalty of 1.5% of net sales, as defined, in each territory to MCRI until such time as any product related to License Agreement II is
no longer sold in the respective territory.

    22

JUPITER
NEUROSCIENCES, INC.

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note
8 – Segment Report

The
Company’s Chief Executive Officer serves as the Chief Operating Decision Maker (“CODM”) and evaluates the financial
performance of the business and makes resource allocation decisions on a consolidated basis.

During
2025, the Company began evaluating a potential realignment of its operations into two reportable segments: (i) the production and sale of premium nutritional
supplements, and (ii) pharmaceutical operations focused on the development of drug candidates. However, as of September 30, 2025, the
CODM has not begun reviewing operating results separately for these activities for purposes of performance assessment or resource allocation.
The CODM continues to evaluate the Company’s financial performance on a consolidated basis, and the internal reporting structure does not provide discrete segment-level financial information.

Management
believes a transitional period is appropriate given the timing of these operational changes. Accordingly, the Company has concluded that
no change in reportable segments has occurred as of September 30, 2025. The Company will continue to monitor the CODM’s review
practices and internal reporting structure and will update segment disclosures in future periods if and when discrete financial information
is regularly reviewed at the segment level.

In accordance with ASC 280-10-50-34, if and when a change in reportable
segments occurs in a future period, the Company will retrospectively recast prior-period segment disclosures to reflect the new segment
structure, presenting historical information on the same basis as then reported. Notwithstanding the foregoing, the Company provides the
entity-wide disclosures required by ASC 280, including information about products and services, geographic areas, and major customers.

Note
9 – Subsequent Events

Note